Jesper Lindahl, Marie Asp, Darya Ståhl, Johanna Tjernberg, Moa Eklund, Johannes Björkstrand, Danielle van Westen, Jimmy Jensen, Kristoffer Månsson, Åsa Tornberg, Martina Svensson, Tomas Deierborg, Filip Ventorp, Daniel Lindqvist
INTRODUCTION: Many depressed patients do not achieve remission with available treatments. Anhedonia is a common residual symptom associated with treatment resistance as well as low function and quality of life. There are currently no specific and effective treatments for anhedonia. Some trials have shown that dopamine agonist pramipexole is efficacious for treating depression, but more data is needed before it could become ready for clinical prime time. Given its mechanism of action, pramipexole might be a useful treatment for a depression subtype characterised by significant anhedonia and lack of motivation-symptoms associated with dopaminergic hypofunction...
November 30, 2023: BMJ Open